Topic: Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognos
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets.
Interesting abstract (the paper is paywalled). It reports the incidence of the IDH1 mutation in ICC as 15.5% based on 200 tumor samples. It also said that patients with "bilateral" tumors, which I understand to mean tumors in both liver lobes, have 2.75 times the likelihood of having the IDH1 mutation. That is starting to get reasonably likely for that type of patient.
Hopefully the IDH1 trial will fill and show a lot of promise.
Great news out of that trial would be fantastic.